Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists

• US 7,514,077 B2
• Filed: 01/10/2007
• Issued: 04/07/2009
• Est. Priority Date: 01/10/2006
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine, Yao, Yue
• Primary Examiner(s): Saoud; Christine J
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US11/621,829
• Publication Number:
  US 20070160610A1
• Time in Patent Office: 818 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claims

1. A method of antagonizing signal transduction in dorsal root ganglion cells in vitro, comprising admixing an antibody with the dorsal root ganglion cells wherein the antibody binds Interleukin 31 (IL-31) and whereby the signal transduction is inhibited.

2. The method of claim 1, wherein the antibody is a monoclonal antibody.

3. The method of claim 1, wherein the antibody is humanized.

4. The method of claim 1, wherein the antibody is an antibody fragment.

5. The method of claim 4, wherein the antibody fragment is selected from the group consisting of:

a) a single-chain antibody;

b) a Fab fragment;

c) a ″

Fab′

fragment; and

d) a F(ab′

)2 fragment.

6. The method of claim 1, wherein the antibody is a chimeric antibody.

7. The method of claim 1, wherein the antibody is produced by the hybridoma selected from the group consisting of:

a) the hybridoma having the ATCC Patent Deposit Designation PTA-6815;

b) the hybridoma having the ATCC Patent Deposit Designation PTA-6816;

c) the hybridoma having the ATCC Patent Deposit Designation PTA-6829;

d) the hybridoma having the ATCC Patent Deposit Designation PTA-6830;

e) the hybridoma having the ATCC Patent Deposit Designation PTA-6831;

f) the hybridoma having the ATCC Patent Deposit Designation PTA-6871;

g) the hybridoma having the ATCC Patent Deposit Designation PTA-6872;

h) the hybridoma having the ATCC Patent Deposit Designation PTA-6875; and

i) the hybridoma having the ATCC Patent Deposit Designation PTA-6873.

8. The method of claim 7, wherein the antibody is humanized.

9. The method of claim 7, wherein the antibody is an antibody fragment.

10. The method of claim 9, wherein the antibody fragment is selected from the group consisting of:

a) a single-chain antibody;

b) a Fab fragment;

c) a ″

Fab′

fragment; and

d) a F(ab′

)2 fragment.

11. The method of claim 7, wherein the antibody is a chimeric antibody.

12. A method of antagonizing signal transduction in dorsal root ganglion cells in vitro, comprising administering an antibody to the dorsal root ganglion cells wherein the antibody binds Interleukin 31 (IL-31) and whereby the signal transduction is inhibited.

13. The method of claim 12, wherein the antibody is a monoclonal antibody.

14. The method of claim 12, wherein the antibody is humanized.

15. The method of claim 12, wherein the antibody is an antibody fragment.

16. The method of claim 15, wherein the antibody fragment is selected from the group consisting of:

a) a single-chain antibody;

b) a Fab fragment;

c) a ″

Fab′

fragment; and

d) a F(ab′

)2 fragment.

17. The method of claim 12, wherein the antibody is a chimeric antibody.

18. The method of claim 12, wherein the antibody is produced by the hybridoma selected from the group consisting of:

a) the hybridoma having the ATCC Patent Deposit Designation PTA-6815;

b) the hybridoma having the ATCC Patent Deposit Designation PTA-6816;

c) the hybridoma having the ATCC Patent Deposit Designation PTA-6829;

d) the hybridoma having the ATCC Patent Deposit Designation PTA-6830;

e) the hybridoma having the ATCC Patent Deposit Designation PTA-6831;

f) the hybridoma having the ATCC Patent Deposit Designation PTA-6871;

g) the hybridoma having the ATCC Patent Deposit Designation PTA-6872;

h) the hybridoma having the ATCC Patent Deposit Designation PTA-6875; and

i) the hybridoma having the ATCC Patent Deposit Designation PTA-6873.

19. The method of claim 18, wherein the antibody is humanized.

20. The method of claim 18, wherein the antibody is an antibody fragment.

21. The method of claim 20, wherein the antibody fragment is selected from the group consisting of:

a) a single-chain antibody;

b) a Fab fragment;

c) a ″

Fab′

fragment; and

d) a F(ab′

)2 fragment.

22. The method of claim 21, wherein the antibody is a chimeric antibody.

23. A method of antagonizing signal transduction in dorsal root ganglion cells in vitro, comprising admixing a receptor with the dorsal root ganglion cells wherein the receptor binds Interleukin 31 (IL-31) and whereby the signal transduction is inhibited.

24. The method of claim 23, wherein the receptor comprises the amino acid sequence of SEQ ID NO:

6.

25. The method of claim 23, wherein the receptor comprises the amino acid of SEQ ID NO:

8.

26. The method of claim 23, wherein the receptor is a soluble receptor comprising the amino acid sequence of SEQ ID NO:

10.

27. The method of claim 23, wherein the receptor is a soluble receptor comprising the amino acid sequence of SEQ ID NO:

12.

28. A method of antagonizing signal transduction in dorsal root ganglion cells in vitro, comprising administering a receptor to the dorsal root ganglion cells wherein the receptor binds Interleukin 31 (IL-31) and whereby the signal transduction is inhibited.

29. The method of claim 28, wherein the receptor comprises the amino acid sequence of SEQ ID NO:

6.

30. The method of claim 28, wherein the receptor comprises the amino acid of SEQ ID NO:

8.

31. The method of claim 28, wherein the receptor is a soluble receptor comprising the amino acid sequence of SEQ ID NO:

10.

32. The method of claim 28, wherein the receptor is a soluble receptor comprising the amino acid sequence of SEQ ID NO:

12.